Skip to main content
Premium Trial:

Request an Annual Quote

GeneTools Competition Sponsorship and Ambion s Silencer Labeled Control siRNAs

Premium

GeneTools, a supplier of morpholinos, said this week that it is sponsoring a competition to generate data directly comparing the properties of siRNAs and morpholinos in gene knockdown experiments in cultured cells.

Under the competition, which is open to any person or group, GeneTools will accept a research proposal outlining the proposed experiments. Five proposals will be selected by March 30. The sponsors of the proposals will be granted $2,000 in research funding, custom morpholinos, and delivery reagent in order to carry out and publish in any peer-reviewed journals the proposed experiments.

The paper with the highest impact factor will be named winner and issued a $10,000 personal check, said GeneTools.

Details of the competition can be found at http://69.59.196.52/genetools/pdfs/competition4.pdf.


Ambion recently introduced Silencer labeled control siRNAs.

According to the company, the siRNAs are fluorescently labeled, allowing direct observation of their cellular uptake, distribution, and localization. The labeling allows researchers to monitor siRNA delivery by fluorescence microscopy, as opposed to unlabeled siRNAs that must be monitored by target gene knockdown.

Additional details about the siRNAs can be found at http://www.ambion.com/catalog/CatNum.php?4620.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.